Pfizer (PFE) stock: analyst price target and their real reliability
Live quote · data updated Aug 28, 2026
Pfizer · Health Care · ref. ETF XLV · 74 calls · price $28.02
What the company does: Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
📈 Pfizer (PFE) stock price
$28.02+13.9% over range
Aug 28, 25low $23.6 · high $28.57Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
33% recommend buying · 12 analysts
📊 JPI status : Pfizer is no longer in our current JPI rankings, but appeared in the past (2024) — its upside may be behind it. See the stocks picked in 2024 →
⚠️ The stock trades above the median target: it has beaten expectations. The “Hold” reflects conviction on the company, but the remaining quantified upside is low/negative.
🎯 PFE price target & analyst consensus — price $28.02
The price target · all analysts combined (12 targets)
Highest target · 1 firm of 12$35+24.9%
Median target · of 12 targets$28-0.1%
Lowest target · 1 firm of 12$25-10.8%
Current price$28.02
Where these 12 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
433%
$30 ↔ $35
Below
867%
$25 ↔ $28
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (239 calls tested). It aims for $30 (+7.1 %), call made on July 14, 2026, maturing on July 14, 2027 (45 d ago).
The 4 reliable analysts
$29+3.5 %
The 8 other firms
$27.50-1.9 %
How to read it: the 4 reliable firms are not filtered by optimism — 2 aim above the price, 2 below, hence their $29 median. “The 8 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 12 ratings (last 6 months)
Strong Buy00%
Buy433%
Hold867%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 PFE price target all
All 74 calls, one by one, with our verdict on each firm.
→ See all 74 targets, analyst by analyst💡 The best analysts on PFE most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in PFE? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Pfizer? The JPI assistant answers using our backtest data.
💰 Pfizer dividend: yield, history & growth › open the full page
7.20%annual yield
📈 Steady dividend — 15 yrs of consecutive dividend increases
That's ~$1.72 per share per year.
📈 Pfizer fundamentals: valuation, margins & growth › open the full page
P/E 37.4Net margin 6.8 %Revenue growth +2.6 %High P/E
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 31 %
2023
Rev −42%Profit −93%
2024
Rev +9%Profit +279%
2025
Rev −2%Profit −3%
🏛️ Pfizer insider buying: who's buying and how much › open the full page
3 insiders bought3 buys / 6 mo $3.0M👥 Cluster buy
🔎 Detailed analyses
🏛️ Which US Congress members hold Pfizer (PFE)?
15 Congress members have disclosed PFE buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Kathy Manning 6× · 43%Lois Frankel 6× · 45%Gilbert Cisneros 5× · 48%Earl Blumenauer 3× · 38%K. Conaway 2× · 30%Mo Brooks 2×Zoe Lofgren 2× · 41%Carol Miller 2× · 25%Rob Bresnahan 2× · 31%Mikie Sherrill 1×
✅ Historical analyst reliability on PFE
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Barclays ↗ | 100% | +14.9% | 2 |
| Atlantic Equities | 100% | +3.8% | 2 |
| Morgan Stanley ↗ | 89% | +9.2% | 9 |
| Guggenheim ↗ | 80% | +2.6% | 5 |
| Citigroup ↗ | 67% | +9.7% | 6 |
| Deutsche Bank ↗ | 67% | +0.3% | 3 |
| Goldman Sachs ↗ | 67% | -3.7% | 3 |
| Jefferies ↗ | 65% | +5.3% | 23 |
| Mizuho ↗ | 50% | +24.7% | 2 |
| RBC Capital ↗ | 50% | +12.5% | 2 |
See the other 10 firms
| Daiwa Capital ↗ | 0% | -25.3% | 2 |
| Wells Fargo ↗ | 0% | -17.6% | 4 |
| Cantor Fitzgerald ↗ | 3% | -14.9% | 30 |
| Truist Securities ↗ | 14% | -5.1% | 7 |
| Argus Research ↗ | 33% | -4.5% | 3 |
| Credit Suisse | 38% | -10.8% | 8 |
| BMO Capital ↗ | 43% | +1.1% | 14 |
| B of A Securities ↗ | 50% | +1.7% | 6 |
| JP Morgan ↗ | 50% | +3.3% | 4 |
| UBS ↗ | 50% | +3.8% | 2 |
📊 What $1,000 invested in Pfizer would be worth › open the full page
In short — $1,000 invested in Pfizer 10 years ago would be worth $855 today, i.e. -2%/yr on average. Best year: 2021 (+40%), worst: 2023 (-35%). Price performance, excluding dividends.
If I'd invested $1,000 in Pfizer
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $911 | -9% |
| 3 years ago | $594 | -41% |
| 5 years ago | $719 | -28% |
Return by year (Pfizer)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | -13% | $871 (-13%) |
| 2025 | +5% | $911 (-9%) |
| 2024 | 0% | $907 (-9%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Pfizer
Loading news…
📋 All analyst calls on PFE
Filtered on — · ✕ show all
Guggenheim ↗
Aug 7, 26
▲ Buy · 🎯$31
Price at call : $27.05 — upside +15%
Today : $28.02 — upside +11%
🎯 on PFE : 100% (4 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Aug 7, 27
matures : Aug 7, 27
BMO Capital ↗
Jul 13, 26
▲ Outperform · 🎯$30
Price at call : $24.48 — upside +23%
Today : $28.02 — upside +7%
🎯 on PFE : no call matured yet · 📊 on Health : 60.7% · +8.8% (239 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
Guggenheim ↗
Jul 13, 26
▲ Buy · 🎯$35
Price at call : $24.48 — upside +43%
Today : $28.02 — upside +25%
🎯 on PFE : 100% (4 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
B of A Securities ↗
Jul 10, 26
■ Neutral neutral · not a buy · 🎯$26
Price at call : $24.48 — gap to target +6%
Today : $28.02 — gap to target -7%
🎯 on PFE : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Jul 10, 27
matures : Jul 10, 27
■ Neutral neutral · not a buy · 🎯$28
Price at call : $24.25 — gap to target +15%
Today : $28.02 — gap to target -0%
🎯 on PFE : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Jul 8, 27
matures : Jul 8, 27
Cantor Fitzgerald ↗
Jul 6, 26
■ Neutral neutral · not a buy · 🎯$27
Price at call : $23.72 — gap to target +14%
Today : $28.02 — gap to target -4%
🎯 on PFE : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Jul 6, 27
matures : Jul 6, 27
■ Hold neutral · not a buy · 🎯$28
Price at call : $23.72 — gap to target +18%
Today : $28.02 — gap to target -0%
🎯 on PFE : no call matured yet · 📊 on Health : 53.6% · +1.4% (28 calls)
in progress (365j)
matures : Jul 6, 27
matures : Jul 6, 27
RBC Capital ↗
Jun 10, 26
■ Sector Perform neutral · not a buy · 🎯$25
Price at call : $26.17 — gap to target -4%
Today : $28.02 — gap to target -11%
🎯 on PFE : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Jun 10, 27
matures : Jun 10, 27
See the other 66 calls, newest to oldest
■ Neutral neutral · not a buy · 🎯$27
Price at call : $26.7 — gap to target +1%
Today : $28.02 — gap to target -4%
🎯 on PFE : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Apr 29, 27
matures : Apr 29, 27
RBC Capital ↗
Apr 20, 26
▼ Underperform · 🎯$25
Price at call : $27.31 — upside -8%
Today : $28.02 — upside -11%
🎯 on PFE : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Apr 20, 27
matures : Apr 20, 27
▲ Outperform · 🎯$33
Price at call : $27.56 — upside +20%
Today : $28.02 — upside +18%
🎯 on PFE : no call matured yet · 📊 overall : 100% · +36.9% (8 calls)
in progress (365j)
matures : Apr 16, 27
matures : Apr 16, 27
■ Neutral neutral · not a buy · 🎯$27
Price at call : $27.11 — gap to target -0%
Today : $28.02 — gap to target -4%
🎯 on PFE : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Apr 13, 27
matures : Apr 13, 27
Morgan Stanley ↗
Apr 10, 26
■ Equal-Weight neutral · not a buy · 🎯$28
Price at call : $27.34 — gap to target +2%
Today : $28.02 — gap to target -0%
🎯 on PFE : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Apr 10, 27
matures : Apr 10, 27
B of A Securities ↗
Apr 9, 26
■ Neutral neutral · not a buy · 🎯$26
Price at call : $26.92 — gap to target -3%
Today : $28.02 — gap to target -7%
🎯 on PFE : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Apr 9, 27
matures : Apr 9, 27
Guggenheim ↗
Mar 24, 26
▲ Buy · 🎯$36
Price at call : $26.96 — upside +34%
Today : $28.02 — upside +28%
🎯 on PFE : 100% (4 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Mar 24, 27
matures : Mar 24, 27
▲ Buy · 🎯$32
Price at call : $27.32 — upside +17%
Today : $28.02 — upside +14%
🎯 on PFE : no call matured yet · 📊 on Health : 53.6% · +1.4% (28 calls)
in progress (365j)
matures : Mar 17, 27
matures : Mar 17, 27
Argus Research ↗
Mar 2, 26
▲ Buy · 🎯$35
Price at call : $26.58 — upside +32%
Today : $28.02 — upside +25%
🎯 on PFE : no call matured yet · 📊 on Health : 55.7% · +2.6% (158 calls)
in progress (365j)
matures : Mar 2, 27
matures : Mar 2, 27
RBC Capital ↗
Feb 25, 26
▼ Underperform · 🎯$25
Price at call : $27.1 — upside -8%
Today : $28.02 — upside -11%
🎯 on PFE : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Feb 25, 27
matures : Feb 25, 27
▼ Underweight · 🎯$25
Price at call : $27.06 — upside -8%
Today : $28.02 — upside -11%
🎯 on PFE : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 20, 27
matures : Feb 20, 27
Freedom Broker
Feb 9, 26
▲ Buy · 🎯$33
Price at call : $27.05 — upside +22%
Today : $28.02 — upside +18%
🎯 on PFE : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Feb 9, 27
matures : Feb 9, 27
Cantor Fitzgerald ↗
Feb 4, 26
■ Neutral neutral · not a buy · 🎯$27
Price at call : $26.49 — gap to target +2%
Today : $28.02 — gap to target -4%
🎯 on PFE : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Feb 4, 27
matures : Feb 4, 27
Cantor Fitzgerald ↗
Jan 27, 26
■ Neutral neutral · not a buy · 🎯$27
Price at call : $25.86 — gap to target +4%
Today : $28.02 — gap to target -4%
🎯 on PFE : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Jan 27, 27
matures : Jan 27, 27
Morgan Stanley ↗
Dec 17, 25
■ Equal-Weight neutral · not a buy · 🎯$27
Price at call : $25.04 — gap to target +8%
Today : $28.02 — gap to target -4%
🎯 on PFE : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Dec 17, 26
matures : Dec 17, 26
B of A Securities ↗
Dec 15, 25
■ Neutral neutral · not a buy · 🎯$28
Price at call : $26.43 — gap to target +6%
Today : $28.02 — gap to target -0%
🎯 on PFE : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Dec 15, 26
matures : Dec 15, 26
Morgan Stanley ↗
Dec 12, 25
■ Equal-Weight neutral · not a buy · 🎯$28
Price at call : $26.43 — gap to target +6%
Today : $28.02 — gap to target -0%
🎯 on PFE : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Dec 12, 26
matures : Dec 12, 26
Guggenheim ↗
Nov 24, 25
▲ Buy · 🎯$35
Price at call : $25.22 — upside +39%
Today : $28.02 — upside +25%
🎯 on PFE : 100% (4 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Nov 24, 26
matures : Nov 24, 26
Morgan Stanley ↗
Oct 10, 25
■ Equal-Weight neutral · not a buy · 🎯$32
Price at call : $24.73 — gap to target +29%
Today : $28.02 — gap to target +14%
🎯 on PFE : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Oct 10, 26
matures : Oct 10, 26
B of A Securities ↗
Oct 3, 25
■ Neutral neutral · not a buy · 🎯$30
Price at call : $27.37 — gap to target +10%
Today : $28.02 — gap to target +7%
🎯 on PFE : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Oct 3, 26
matures : Oct 3, 26
■ Neutral neutral · not a buy · 🎯$26
Price at call : $24.23 — gap to target +7%
Today : $28.02 — gap to target -7%
🎯 on PFE : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Aug 7, 26
matures : Aug 7, 26
Morgan Stanley ↗
Aug 6, 25
■ Equal-Weight neutral · not a buy · 🎯$33
Price at call : $24.23 — gap to target +36%
Today : $28.02 — gap to target +18%
🎯 on PFE : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Aug 6, 26
matures : Aug 6, 26
B of A Securities ↗
Aug 6, 25
■ Neutral neutral · not a buy · 🎯$28
Price at call : $23.93 — gap to target +17%
Today : $28.02 — gap to target -0%
🎯 on PFE : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Aug 6, 26
matures : Aug 6, 26
■ Neutral neutral · not a buy · 🎯$25
Price at call : $23.93 — gap to target +4%
Today : $28.02 — gap to target -11%
🎯 on PFE : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Apr 30, 26
matures : Apr 30, 26
Cantor Fitzgerald ↗
Apr 22, 25
■ Neutral neutral · not a buy · 🎯$24
Price at call : $22.53 — gap to target +7%
Today : $28.02 — gap to target -14%
🎯 on PFE : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Apr 22, 26
matures : Apr 22, 26
■ Neutral neutral · not a buy · 🎯$24
Price at call : $22.49 — gap to target +7%
Today : $28.02 — gap to target -14%
🎯 on PFE : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Apr 8, 26
matures : Apr 8, 26
Goldman Sachs ↗
Apr 8, 25
■ Neutral neutral · not a buy · 🎯$25
Price at call : $22.49 — gap to target +11%
Today : $28.02 — gap to target -11%
🎯 on PFE : no call matured yet · 📊 on Health : 50.8% · +2.0% (240 calls)
in progress (365j)
matures : Apr 8, 26
matures : Apr 8, 26
Guggenheim ↗
Mar 18, 25
▲ Buy
Actual +5% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 100% (4 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
+4.6%
stock +5% · XLV -0%
matured Mar 18, 26
Guggenheim ↗
Mar 12, 25
▲ Buy
Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 100% (4 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
+3.8%
stock +4% · XLV +4%
matured Mar 12, 26
Guggenheim ↗
Feb 10, 25
▲ Buy · 🎯$33
Price at call : $25.87 — upside +28%
Today : $28.02 — upside +18%
Expected +28% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 100% (4 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
+6.7%
stock +7% · XLV +6%
matured Feb 10, 26
■ Neutral neutral · not a buy · 🎯$28
Price at call : $26.44 — gap to target +6%
Today : $28.02 — gap to target -0%
🎯 on PFE : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Feb 5, 26
matures : Feb 5, 26
■ Neutral neutral · not a buy · 🎯$29
Price at call : $26.75 — gap to target +8%
Today : $28.02 — gap to target +3%
🎯 on PFE : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Jan 28, 26
matures : Jan 28, 26
■ Neutral neutral · not a buy · 🎯$29
Price at call : $26.72 — gap to target +9%
Today : $28.02 — gap to target +3%
🎯 on PFE : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Jan 8, 26
matures : Jan 8, 26
Truist Securities ↗
Dec 18, 24
▲ Buy · 🎯$32
Price at call : $25.77 — upside +24%
Today : $28.02 — upside +14%
Expected +24% · Actual -2% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 0% (1 call matured) · 📊 on Health : 49.6% · +2.3% (260 calls)
-2.3%
stock -2% · XLV +14%
matured Dec 18, 25
Guggenheim ↗
Dec 11, 24
▲ Buy · 🎯$33
Price at call : $25.37 — upside +30%
Today : $28.02 — upside +18%
Expected +30% · Actual +2% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 100% (4 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
+1.9%
stock +2% · XLV +9%
matured Dec 11, 25
Wolfe Research ↗
Nov 15, 24
▼ Underperform · 🎯$25
Price at call : $24.8 — upside +1%
Today : $28.02 — upside -11%
Expected +1% · Actual +1% · Reason (≤ −15%) : ✗ No
🎯 on PFE : 0% (1 call matured) · 📊 on Health : 60.9% · +4.3% (46 calls)
-1.1%
stock +1% · XLV +7%
matured Nov 15, 25
Morgan Stanley ↗
Oct 30, 24
■ Equal-Weight neutral · not a buy · 🎯$31
Price at call : $28.52 — gap to target +9%
Today : $28.02 — gap to target +11%
🎯 on PFE : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Oct 30, 25
matures : Oct 30, 25
Cantor Fitzgerald ↗
Oct 25, 24
▲ Overweight · 🎯$45
Price at call : $28.86 — upside +56%
Today : $28.02 — upside +61%
Expected +56% · Actual -14% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-14.2%
stock -14% · XLV -2%
matured Oct 25, 25
Cantor Fitzgerald ↗
Oct 23, 24
▲ Overweight · 🎯$45
Price at call : $28.64 — upside +57%
Today : $28.02 — upside +61%
Expected +57% · Actual -14% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-13.6%
stock -14% · XLV -2%
matured Oct 23, 25
■ Market Perform neutral · not a buy · 🎯$32
Price at call : $29.27 — gap to target +9%
Today : $28.02 — gap to target +14%
🎯 on PFE : no call matured yet · 📊 on Health : 54.7% · +5.2% (64 calls)
in progress (365j)
matures : Oct 17, 25
matures : Oct 17, 25
Morgan Stanley ↗
Oct 11, 24
■ Equal-Weight neutral · not a buy · 🎯$30
Price at call : $29.16 — gap to target +3%
Today : $28.02 — gap to target +7%
🎯 on PFE : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Oct 11, 25
matures : Oct 11, 25
Cantor Fitzgerald ↗
Oct 3, 24
▲ Overweight · 🎯$45
Price at call : $28.58 — upside +57%
Today : $28.02 — upside +61%
Expected +57% · Actual -8% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-7.5%
stock -8% · XLV -5%
matured Oct 3, 25
Cantor Fitzgerald ↗
Sep 16, 24
▲ Overweight · 🎯$45
Price at call : $29.83 — upside +51%
Today : $28.02 — upside +61%
Expected +51% · Actual -19% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-19.4%
stock -19% · XLV -12%
matured Sep 16, 25
Cantor Fitzgerald ↗
Sep 9, 24
▲ Overweight · 🎯$45
Price at call : $29.74 — upside +51%
Today : $28.02 — upside +61%
Expected +51% · Actual -17% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-17.4%
stock -17% · XLV -12%
matured Sep 9, 25
Cantor Fitzgerald ↗
Aug 19, 24
▲ Overweight · 🎯$45
Price at call : $28.9 — upside +56%
Today : $28.02 — upside +61%
Expected +56% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-12.2%
stock -12% · XLV -11%
matured Aug 19, 25
Daiwa Capital ↗
Aug 8, 24
▲ Outperform · 🎯$34
Price at call : $28.55 — upside +19%
Today : $28.02 — upside +21%
Expected +19% · Actual -14% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 0% (2 calls matureds) · 📊 on Health : 40% · -1.0% (5 calls)
-13.9%
stock -14% · XLV -13%
matured Aug 8, 25
Cantor Fitzgerald ↗
Jul 31, 24
▲ Overweight · 🎯$45
Price at call : $30.65 — upside +47%
Today : $28.02 — upside +61%
Expected +47% · Actual -23% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-23.4%
stock -23% · XLV -13%
matured Jul 31, 25
Cantor Fitzgerald ↗
Jul 10, 24
▲ Overweight · 🎯$45
Price at call : $28.66 — upside +57%
Today : $28.02 — upside +61%
Expected +57% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-10.5%
stock -11% · XLV -8%
matured Jul 10, 25
Cantor Fitzgerald ↗
Jul 1, 24
▲ Overweight · 🎯$45
Price at call : $27.83 — upside +62%
Today : $28.02 — upside +61%
Expected +62% · Actual -9% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-9.0%
stock -9% · XLV -6%
matured Jul 1, 25
Cantor Fitzgerald ↗
Jun 26, 24
▲ Overweight · 🎯$45
Price at call : $27.8 — upside +62%
Today : $28.02 — upside +61%
Expected +62% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-13.0%
stock -13% · XLV -8%
matured Jun 26, 25
Cantor Fitzgerald ↗
Jun 20, 24
▲ Overweight · 🎯$45
Price at call : $27.74 — upside +62%
Today : $28.02 — upside +61%
Expected +62% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-13.4%
stock -13% · XLV -10%
matured Jun 20, 25
Cantor Fitzgerald ↗
Jun 17, 24
▲ Overweight · 🎯$45
Price at call : $27.41 — upside +64%
Today : $28.02 — upside +61%
Expected +64% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
-12.9%
stock -13% · XLV -9%
matured Jun 17, 25
▲ Buy · 🎯$39
Price at call : $33.27 — upside +17%
Today : $28.02 — upside +39%
Expected +17% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 33% (12 calls matureds) · 📊 on Health : 50.8% · +4.5% (380 calls)
-11.5%
stock -12% · XLV +17%
matured Oct 15, 24
Daiwa Capital ↗
May 11, 23
■ Neutral neutral · not a buy · 🎯$38
Price at call : $37.58 — gap to target +1%
Today : $28.02 — gap to target +36%
🎯 on PFE : 0% (2 calls matureds) · 📊 on Health : 40% · -1.0% (5 calls)
in progress (365j)
matures : May 10, 24
matures : May 10, 24
Daiwa Capital ↗
Feb 7, 23
▲ Outperform · 🎯$51
Price at call : $43.59 — upside +17%
Today : $28.02 — upside +82%
Expected +17% · Actual -37% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 0% (2 calls matureds) · 📊 on Health : 40% · -1.0% (5 calls)
-36.8%
stock -37% · XLV +9%
matured Feb 7, 24
▲ Buy · 🎯$39
Price at call : $32.3 — upside +21%
Today : $28.02 — upside +39%
Expected +21% · Actual +3% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 33% (12 calls matureds) · 📊 on Health : 50.8% · +4.5% (380 calls)
+3.0%
stock +3% · XLV +16%
matured Sep 13, 17
▲ Buy · 🎯$40
Price at call : $33.62 — upside +19%
Today : $28.02 — upside +43%
Expected +19% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 33% (12 calls matureds) · 📊 on Health : 50.8% · +4.5% (380 calls)
-6.0%
stock -6% · XLV +6%
matured Aug 4, 17
▲ Buy · 🎯$41.5
Price at call : $34.89 — upside +19%
Today : $28.02 — upside +48%
Expected +19% · Actual -10% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 33% (12 calls matureds) · 📊 on Health : 50.8% · +4.5% (380 calls)
-9.6%
stock -10% · XLV +8%
matured Jul 14, 17
▲ Buy · 🎯$40
Price at call : $32.73 — upside +22%
Today : $28.02 — upside +43%
Expected +22% · Actual -3% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 33% (12 calls matureds) · 📊 on Health : 50.8% · +4.5% (380 calls)
-2.7%
stock -3% · XLV +12%
matured Jun 20, 17
▲ Buy · 🎯$42
Price at call : $33.01 — upside +27%
Today : $28.02 — upside +50%
Expected +27% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 33% (12 calls matureds) · 📊 on Health : 50.8% · +4.5% (380 calls)
-5.7%
stock -6% · XLV +10%
matured Jun 14, 17
▲ Buy · 🎯$39
Price at call : $30.83 — upside +27%
Today : $28.02 — upside +39%
Expected +27% · Actual +5% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 33% (12 calls matureds) · 📊 on Health : 50.8% · +4.5% (380 calls)
+4.7%
stock +5% · XLV +7%
matured Apr 7, 17
▲ Buy · 🎯$45
Price at call : $29.23 — upside +54%
Today : $28.02 — upside +61%
Expected +54% · Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 33% (12 calls matureds) · 📊 on Health : 50.8% · +4.5% (380 calls)
+4.1%
stock +4% · XLV +6%
matured Jan 13, 17
▲ Buy · 🎯$47
Price at call : $33.55 — upside +40%
Today : $28.02 — upside +68%
Expected +40% · Actual -1% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 33% (12 calls matureds) · 📊 on Health : 50.8% · +4.5% (380 calls)
-1.2%
stock -1% · XLV -2%
matured Aug 6, 16
▲ Overweight · 🎯$45
Price at call : $32.24 — upside +40%
Today : $28.02 — upside +61%
Expected +40% · Actual +2% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 33% (12 calls matureds) · 📊 on Health : 50.8% · +4.5% (380 calls)
+2.3%
stock +2% · XLV -5%
matured Jun 16, 16
▲ Buy · 🎯$45
Price at call : $33.25 — upside +35%
Today : $28.02 — upside +61%
Expected +35% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on PFE : 33% (12 calls matureds) · 📊 on Health : 50.8% · +4.5% (380 calls)
-13.3%
stock -13% · XLV -9%
matured Mar 22, 16
Frequently asked questions
Should I buy Pfizer stock?
This isn't buy advice. For Pfizer, the analyst consensus is "Hold", with an average price target of $28.00 (0% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Pfizer). We show the numbers — you decide.
Is it too late to buy Pfizer? How high can it go?
The most bullish analyst target on Pfizer is $35.00 (+25% above today's price); the average is $28.00. That's the upside they see. Check how reliable those analysts have actually been on Pfizer on our site before trusting it.
Is Pfizer still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 20 analysts have a real record on Pfizer, the best hitting 100% over 2 calls. Current consensus: "Hold". Make your call on data, not noise.
Should you invest in Pfizer? The case for and against
The arguments for and against, one by one, from the numbers: why invest in PFE (and why hesitate).
What has Pfizer's past performance been?
Historical returns and a "how much if I had invested" calculator: PFE performance & returns.
Does Pfizer pay a dividend?
Yield, consistency and growth history of the dividend: PFE's dividend.
What is the best month to buy PFE?
The 12 months ranked by the stock's past returns: best & worst month to buy PFE.
Are insiders buying PFE stock?
Executives' and large holders' buys and sells, decoded: insider buying on PFE.
BIIB 
VRTX 
UNH 
REGN 
EW 
SRPT 
VEEV 
BSX